Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
Zechmann, Christian M
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. [electronic resource] - European journal of nuclear medicine and molecular imaging Jul 2014 - 1280-92 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1619-7089
10.1007/s00259-014-2713-y doi
Aged
Antigens, Surface--metabolism
Glutamate Carboxypeptidase II--metabolism
Glutamates--adverse effects
Humans
Iodine Radioisotopes--therapeutic use
Male
Middle Aged
Molecular Targeted Therapy--adverse effects
Neoplasm Metastasis
Organs at Risk--radiation effects
Positron-Emission Tomography
Prostatic Neoplasms--diagnostic imaging
Radiometry
Radiopharmaceuticals--adverse effects
Radiotherapy Dosage
Safety
Tomography, X-Ray Computed
Treatment Outcome
Urea--adverse effects
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. [electronic resource] - European journal of nuclear medicine and molecular imaging Jul 2014 - 1280-92 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1619-7089
10.1007/s00259-014-2713-y doi
Aged
Antigens, Surface--metabolism
Glutamate Carboxypeptidase II--metabolism
Glutamates--adverse effects
Humans
Iodine Radioisotopes--therapeutic use
Male
Middle Aged
Molecular Targeted Therapy--adverse effects
Neoplasm Metastasis
Organs at Risk--radiation effects
Positron-Emission Tomography
Prostatic Neoplasms--diagnostic imaging
Radiometry
Radiopharmaceuticals--adverse effects
Radiotherapy Dosage
Safety
Tomography, X-Ray Computed
Treatment Outcome
Urea--adverse effects